Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2014 Jun;73(6):1303-6. doi: 10.1007/s00280-014-2462-4. Epub 2014 Apr 6.

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction.

Author information

1
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, PO Box 9600 NL, 2300 RC, Leiden, The Netherlands, l.l.krens@lumc.nl.

Abstract

INTRODUCTION:

In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to prior chemotherapy, who was treated on compassionate use basis with 400 mg/m(2) cetuximab.

MATERIAL AND METHODS:

Pharmacokinetic parameters after the first dose, including dose-normalised AUC from time zero to day 7, clearance, elimination half-life (t(1/2)), were estimated using trapezoidal non-compartmental methods and compared to pharmacokinetic data from a study population with normal kidney function.

RESULTS:

The results showed that the pharmacokinetics of cetuximab in this patient with renal failure was similar to that with adequate renal function.

CONCLUSION:

This study suggests that cetuximab can be safely used in cancer patients with renal impairment without dose adjustment.

PMID:
24705976
DOI:
10.1007/s00280-014-2462-4
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Springer Icon for HAL archives ouvertes
Loading ...
Support Center